beta blocker: be contraindicated in patients with asthma

from Quasimodo
0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Related concepts

Parents agent
Weight: 0.65
, high blood pressure
Weight: 0.63
, heart disease
Weight: 0.63
, vasodilator
Weight: 0.62
Siblings atenolol
Weight: 0.53
, lung cancer
Weight: 0.33
, cystic fibrosis
Weight: 0.33
, agonist
Weight: 0.32
, blood clot
Weight: 0.32

Related properties

Property Similarity
be contraindicated in patients with asthma 1.00
be contraindicated with asthma 0.98
be contraindicated in asthma 0.98
be contraindicated in patients 0.96
be contraindicated in diabetes 0.94
be contraindicated in angina 0.94
be contraindicated in vasospastic angina 0.94
be contraindicated in disease 0.93
be contraindicated in diabetes mellitus 0.93
be contraindicated in myasthenia gravis 0.92

Priors about this statement

Cues

0.2 0.4 0.6 0.8 Joint Necessity Sufficiency Implication Entailment Contradiction Entropy

Evidence

0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Clauses

Remarkability exclusitivity between siblings

0.07
Rule weight: 0.13
Evidence weight: 0.57
Similarity weight: 0.98
Evidence: 0.67
¬ Remarkable(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.65
¬ Remarkable(atenolol, be contraindicated in asthma)

Remarkability from sibling implausibility

0.55
Rule weight: 0.60
Evidence weight: 0.94
Similarity weight: 0.98
Evidence: 0.78
Plausible(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.65
Remarkable(atenolol, be contraindicated in asthma) ⋁
Evidence: 0.75
¬ Plausible(atenolol, be contraindicated in asthma)

Salient implies Plausible

0.23
Rule weight: 0.28
Evidence weight: 0.81
Similarity weight: 1.00
Evidence: 0.78
Plausible(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.87
¬ Salient(beta blocker, be contraindicated in patients with asthma)

Similarity expansion

0.75
Rule weight: 0.85
Evidence weight: 0.90
Similarity weight: 0.98
Evidence: 0.87
Salient(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.79
¬ Salient(beta blocker, be contraindicated with asthma)
0.74
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.98
Evidence: 0.87
Salient(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.84
¬ Salient(beta blocker, be contraindicated in asthma)
0.73
Rule weight: 0.85
Evidence weight: 0.93
Similarity weight: 0.92
Evidence: 0.82
Typical(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.40
¬ Typical(beta blocker, be contraindicated in myasthenia gravis)
0.73
Rule weight: 0.85
Evidence weight: 0.88
Similarity weight: 0.98
Evidence: 0.82
Typical(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.67
¬ Typical(beta blocker, be contraindicated in asthma)
0.72
Rule weight: 0.85
Evidence weight: 0.87
Similarity weight: 0.98
Evidence: 0.82
Typical(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.72
¬ Typical(beta blocker, be contraindicated with asthma)
0.72
Rule weight: 0.85
Evidence weight: 0.90
Similarity weight: 0.94
Evidence: 0.87
Salient(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.79
¬ Salient(beta blocker, be contraindicated in vasospastic angina)
0.71
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.94
Evidence: 0.87
Salient(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.85
¬ Salient(beta blocker, be contraindicated in diabetes)
0.71
Rule weight: 0.85
Evidence weight: 0.91
Similarity weight: 0.92
Evidence: 0.87
Salient(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.72
¬ Salient(beta blocker, be contraindicated in myasthenia gravis)
0.71
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.98
Evidence: 0.78
Plausible(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.69
¬ Plausible(beta blocker, be contraindicated with asthma)
0.71
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.98
Evidence: 0.78
Plausible(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.69
¬ Plausible(beta blocker, be contraindicated in asthma)
0.70
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.93
Evidence: 0.87
Salient(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.87
¬ Salient(beta blocker, be contraindicated in diabetes mellitus)
0.70
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.92
Evidence: 0.78
Plausible(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.51
¬ Plausible(beta blocker, be contraindicated in myasthenia gravis)
0.69
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.94
Evidence: 0.82
Typical(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.74
¬ Typical(beta blocker, be contraindicated in vasospastic angina)
0.69
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.94
Evidence: 0.82
Typical(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.80
¬ Typical(beta blocker, be contraindicated in diabetes)
0.68
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.93
Evidence: 0.82
Typical(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.81
¬ Typical(beta blocker, be contraindicated in diabetes mellitus)
0.68
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.94
Evidence: 0.78
Plausible(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.70
¬ Plausible(beta blocker, be contraindicated in vasospastic angina)
0.67
Rule weight: 0.85
Evidence weight: 0.83
Similarity weight: 0.94
Evidence: 0.78
Plausible(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.76
¬ Plausible(beta blocker, be contraindicated in diabetes)
0.66
Rule weight: 0.85
Evidence weight: 0.83
Similarity weight: 0.93
Evidence: 0.78
Plausible(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.78
¬ Plausible(beta blocker, be contraindicated in diabetes mellitus)
0.65
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.98
Evidence: 0.67
Remarkable(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated with asthma)
0.63
Rule weight: 0.85
Evidence weight: 0.79
Similarity weight: 0.94
Evidence: 0.67
Remarkable(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.64
¬ Remarkable(beta blocker, be contraindicated in vasospastic angina)
0.63
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.94
Evidence: 0.67
Remarkable(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.66
¬ Remarkable(beta blocker, be contraindicated in diabetes)
0.62
Rule weight: 0.85
Evidence weight: 0.75
Similarity weight: 0.98
Evidence: 0.67
Remarkable(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.77
¬ Remarkable(beta blocker, be contraindicated in asthma)
0.62
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.93
Evidence: 0.67
Remarkable(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in diabetes mellitus)
0.56
Rule weight: 0.85
Evidence weight: 0.72
Similarity weight: 0.92
Evidence: 0.67
Remarkable(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.86
¬ Remarkable(beta blocker, be contraindicated in myasthenia gravis)

Typical and Remarkable implies Salient

0.13
Rule weight: 0.14
Evidence weight: 0.93
Similarity weight: 1.00
Evidence: 0.87
Salient(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.82
¬ Typical(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.67
¬ Remarkable(beta blocker, be contraindicated in patients with asthma)

Typical implies Plausible

0.39
Rule weight: 0.48
Evidence weight: 0.82
Similarity weight: 1.00
Evidence: 0.78
Plausible(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.82
¬ Typical(beta blocker, be contraindicated in patients with asthma)

Typicality and Rermarkability incompatibility between siblings

0.06
Rule weight: 0.14
Evidence weight: 0.47
Similarity weight: 0.98
Evidence: 0.67
¬ Remarkable(beta blocker, be contraindicated in patients with asthma) ⋁
Evidence: 0.79
¬ Typical(atenolol, be contraindicated in asthma)